Early detection. Personalized treatments. Collaborative care. The Center for Alzheimer’s Disease Research is positioning Brown to improve patient outcomes now and in the future.
Brown researchers are pursuing a promising new method that could transform toxicology testing, making it faster and more effective without the use of animals.
By blurring the line between patient care and clinical research, this dual degree might be our best chance to tackle some of the most pressing health issues of our time.
Generous gifts totalling $30 million are supporting the establishment of the Center for Alzheimer’s Disease Research at Brown, with a focus on early detection and viable treatments.
Sandi Nusinoff Lehrman ’69 MD’76 and Stephen A. Lehrman ’73 have seen two grandchildren battle a rare neurological disease. Through their philanthropy, they're supporting Brown's Center for Translational Neuroscience in its crusade to discover new treatments for rare brain diseases.
Cancer doesn’t take a break, not even for a worldwide pandemic. The newly established Cancer Center at Brown University, directed by Dr. Wafik El-Deiry, is making sure advances in research and improvements to patient care continue uninterrupted.
From providing emergency support to students during a global pandemic to game-changing research in malaria, we're looking back at some important accomplishments supported by Brown donors in a year that was anything but ordinary.
Recent hires, game-changing grants, and collaboration are helping to position Brown’s Carney Institute for Brain Science as a global leader in Alzheimer’s research and treatment.
As a practicing emergency physician, Dr. Megan Ranney MPH’10 RES’08 believes that the emergency department is where you can change a patient’s health care trajectory. And technology is her tool of choice.
Professor Eric Morrow and his team of researchers are using genetics to speed up the diagnosis and treatment of autism in children—and to provide hope to families.
Brown’s new Biomedical Innovation Fund has made two grants to accelerate the commercialization of technologies — one for diagnosing drug dependence in newborns and a second for discovering anti-ALS medicines.